Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $4,034,094.20 in Stock

Key Points

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, sold 8,924 shares for over $4 million, decreasing her ownership by 12.01% to approximately $29.5 million.
• The company's stock has seen a slight decline of 1.0%, with current trading at $456.35, while its market cap is around $59.82 billion.
• Alnylam Pharmaceuticals recently reported quarterly earnings of $0.32 EPS, significantly surpassing the estimated loss of $0.54, with revenue up 17.3% year-over-year.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 8,924 shares of the business's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company's stock, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, August 18th, Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33.

Alnylam Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ:ALNY traded down $4.64 during trading hours on Friday, hitting $456.35. The company's stock had a trading volume of 969,084 shares, compared to its average volume of 982,632. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The company has a market capitalization of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The firm's fifty day moving average price is $439.02 and its 200 day moving average price is $337.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the business posted ($0.13) EPS. The company's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ALNY. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Jefferies Financial Group boosted their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $439.58.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the company. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $30,000. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $27,000. Whipplewood Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $37,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.